NGC 1058: Gas motions in an extended, quiescent spiral disk

Researchers investigate in detail the motion of gas in the galaxy NGC 1058 using the very large array (VLA) to map the emission in the 21-cm line. This galaxy is so nearly face-on that the contribution to the line width due to the variation of the rotational velocity across the D-array beam is small compared with the random z-motion of the gas. Researchers confirm results of earlier studies (Lewis 1987, A. and A. Suppl., 63, 515; van der Kruit and Shostak 1984, A. and A., 134, 258) of the galaxy's total neutral hydrogen (HI) and kinematics, including the fact that the rotation curve drops faster than Keplerian at the outer edge of the disk, which is interpreted as a fortuitous twist of the plane of rotation in the outer disk. However, their very high velocity resolution (2.58 km s(exp -1) after Hanning smoothing) coupled with good spatial resolution, allows researchers to measure more accurately the line width, and even to some extent its shape, throughout the disk. One of the most interesting results of this study is the remarkable constancy of the line width in the outer disk. From radius 90 to 210 seconds the Gaussian velocity dispersion (sigma sub nu) of the 21-cm line has a mean value of 5.7 km s(exp -1) (after correcting for the spectral resolution) with a dispersion of less than 0.9 km s(exp -1) (after correcting for the spectral resolution) with a dispersion of less than 0.9 km s(exp -1). Translating this directly into a kinetic temperature (Doppler temperature): T sub Dopp equals 121K (sigma sub mu exp 2/(km s(exp -1) (exp 2) gives 4000 K, with a dispersion of less than 1500 K over the outer disk. This constancy is observed even when comparing the spiral arms versus inter-arm regions, which in the radius range from 100 to 150 seconds the surface density modulates (defined as the ratio N sub peak -N sub trough/N sub peak + N sub trough) from 0.5 to 0.25 in the range 150 to 200 seconds

Interstellar gas and dust in the young cluster IC 348

We have completed a multiband absorption- and emission-line study of a star embedded in the young cluster IC 348, to determine the environmental effect of star formation on the interstellar medium (ISM) local to the region. The hottest and youngest star in IC 348 is BD+31°643, a B5 V star which samples the inner bright nebular region. The nearby star o Per, which lies only 8 to the north and is thought to lie beyond IC 348, samples the gas and dust which has not been processed by very recent star formation. We speculate that the ISM throughout the region was originally the same as that currently seen toward o Per, but now the contrasting environmental conditions due to the recent star formation have led to marked differences in the atomic, molecular, and dust characteristics of IC 348. These contrasts include what we have termed a ``composite\u27\u27 UV extinction curve for BD+31°643, evidence for enhanced density and enhanced depletions within IC 348 and very different molecular abundances in the interstellar sightline to BD+31°643. Toward BD+31°643, we find a higher column density of CH, but lower CN and very much higher CH + than measured toward o Per. We conclude that the physical and chemical state of the gas and dust has been altered by local processes and conditions within IC 348. The characteristics of the ISM in IC 348, via our study of the star BD+31°643, closely resemble those seen toward Oph, another sight line passing through a bright nebular region. However, the stars are not as hot in IC 348 as in Ophiuchus, so their effect on the local ISM is not as severe

Interstellar gas and dust in the young cluster IC 348

We have completed a multiband absorption- and emission-line study of a star embedded in the young cluster IC 348, to determine the environmental effect of star formation on the interstellar medium (ISM) local to the region. The hottest and youngest star in IC 348 is BD+31°643, a B5 V star which samples the inner bright nebular region. The nearby star o Per, which lies only 8 to the north and is thought to lie beyond IC 348, samples the gas and dust which has not been processed by very recent star formation. We speculate that the ISM throughout the region was originally the same as that currently seen toward o Per, but now the contrasting environmental conditions due to the recent star formation have led to marked differences in the atomic, molecular, and dust characteristics of IC 348. These contrasts include what we have termed a ``composite\u27\u27 UV extinction curve for BD+31°643, evidence for enhanced density and enhanced depletions within IC 348 and very different molecular abundances in the interstellar sightline to BD+31°643. Toward BD+31°643, we find a higher column density of CH, but lower CN and very much higher CH + than measured toward o Per. We conclude that the physical and chemical state of the gas and dust has been altered by local processes and conditions within IC 348. The characteristics of the ISM in IC 348, via our study of the star BD+31°643, closely resemble those seen toward Oph, another sight line passing through a bright nebular region. However, the stars are not as hot in IC 348 as in Ophiuchus, so their effect on the local ISM is not as severe

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial

Background: Glucagon-like peptide 1 receptor agonists differ in chemical structure, duration of action, and in their effects on clinical outcomes. The cardiovascular effects of once-weekly albiglutide in type 2 diabetes are unknown. We aimed to determine the safety and efficacy of albiglutide in preventing cardiovascular death, myocardial infarction, or stroke. Methods: We did a double-blind, randomised, placebo-controlled trial in 610 sites across 28 countries. We randomly assigned patients aged 40 years and older with type 2 diabetes and cardiovascular disease (at a 1:1 ratio) to groups that either received a subcutaneous injection of albiglutide (30–50 mg, based on glycaemic response and tolerability) or of a matched volume of placebo once a week, in addition to their standard care. Investigators used an interactive voice or web response system to obtain treatment assignment, and patients and all study investigators were masked to their treatment allocation. We hypothesised that albiglutide would be non-inferior to placebo for the primary outcome of the first occurrence of cardiovascular death, myocardial infarction, or stroke, which was assessed in the intention-to-treat population. If non-inferiority was confirmed by an upper limit of the 95% CI for a hazard ratio of less than 1·30, closed testing for superiority was prespecified. This study is registered with ClinicalTrials.gov, number NCT02465515. Findings: Patients were screened between July 1, 2015, and Nov 24, 2016. 10 793 patients were screened and 9463 participants were enrolled and randomly assigned to groups: 4731 patients were assigned to receive albiglutide and 4732 patients to receive placebo. On Nov 8, 2017, it was determined that 611 primary endpoints and a median follow-up of at least 1·5 years had accrued, and participants returned for a final visit and discontinuation from study treatment; the last patient visit was on March 12, 2018. These 9463 patients, the intention-to-treat population, were evaluated for a median duration of 1·6 years and were assessed for the primary outcome. The primary composite outcome occurred in 338 (7%) of 4731 patients at an incidence rate of 4·6 events per 100 person-years in the albiglutide group and in 428 (9%) of 4732 patients at an incidence rate of 5·9 events per 100 person-years in the placebo group (hazard ratio 0·78, 95% CI 0·68–0·90), which indicated that albiglutide was superior to placebo (p<0·0001 for non-inferiority; p=0·0006 for superiority). The incidence of acute pancreatitis (ten patients in the albiglutide group and seven patients in the placebo group), pancreatic cancer (six patients in the albiglutide group and five patients in the placebo group), medullary thyroid carcinoma (zero patients in both groups), and other serious adverse events did not differ between the two groups. There were three (<1%) deaths in the placebo group that were assessed by investigators, who were masked to study drug assignment, to be treatment-related and two (<1%) deaths in the albiglutide group. Interpretation: In patients with type 2 diabetes and cardiovascular disease, albiglutide was superior to placebo with respect to major adverse cardiovascular events. Evidence-based glucagon-like peptide 1 receptor agonists should therefore be considered as part of a comprehensive strategy to reduce the risk of cardiovascular events in patients with type 2 diabetes. Funding: GlaxoSmithKline

Optimasi Portofolio Resiko Menggunakan Model Markowitz MVO Dikaitkan dengan Keterbatasan Manusia dalam Memprediksi Masa Depan dalam Perspektif Al-Qur`an

Risk portfolio on modern finance has become increasingly technical, requiring the use of sophisticated mathematical tools in both research and practice. Since companies cannot insure themselves completely against risk, as human incompetence in predicting the future precisely that written in Al-Quran surah Luqman verse 34, they have to manage it to yield an optimal portfolio. The objective here is to minimize the variance among all portfolios, or alternatively, to maximize expected return among all portfolios that has at least a certain expected return. Furthermore, this study focuses on optimizing risk portfolio so called Markowitz MVO (Mean-Variance Optimization). Some theoretical frameworks for analysis are arithmetic mean, geometric mean, variance, covariance, linear programming, and quadratic programming. Moreover, finding a minimum variance portfolio produces a convex quadratic programming, that is minimizing the objective function ðð¥with constraintsð ð 𥠥 ðandð´ð¥ = ð. The outcome of this research is the solution of optimal risk portofolio in some investments that could be finished smoothly using MATLAB R2007b software together with its graphic analysis

Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial.

Importance: Evidence regarding corticosteroid use for severe coronavirus disease 2019 (COVID-19) is limited. Objective: To determine whether hydrocortisone improves outcome for patients with severe COVID-19. Design, Setting, and Participants: An ongoing adaptive platform trial testing multiple interventions within multiple therapeutic domains, for example, antiviral agents, corticosteroids, or immunoglobulin. Between March 9 and June 17, 2020, 614 adult patients with suspected or confirmed COVID-19 were enrolled and randomized within at least 1 domain following admission to an intensive care unit (ICU) for respiratory or cardiovascular organ support at 121 sites in 8 countries. Of these, 403 were randomized to open-label interventions within the corticosteroid domain. The domain was halted after results from another trial were released. Follow-up ended August 12, 2020. Interventions: The corticosteroid domain randomized participants to a fixed 7-day course of intravenous hydrocortisone (50 mg or 100 mg every 6 hours) (n = 143), a shock-dependent course (50 mg every 6 hours when shock was clinically evident) (n = 152), or no hydrocortisone (n = 108). Main Outcomes and Measures: The primary end point was organ support-free days (days alive and free of ICU-based respiratory or cardiovascular support) within 21 days, where patients who died were assigned -1 day. The primary analysis was a bayesian cumulative logistic model that included all patients enrolled with severe COVID-19, adjusting for age, sex, site, region, time, assignment to interventions within other domains, and domain and intervention eligibility. Superiority was defined as the posterior probability of an odds ratio greater than 1 (threshold for trial conclusion of superiority >99%). Results: After excluding 19 participants who withdrew consent, there were 384 patients (mean age, 60 years; 29% female) randomized to the fixed-dose (n = 137), shock-dependent (n = 146), and no (n = 101) hydrocortisone groups; 379 (99%) completed the study and were included in the analysis. The mean age for the 3 groups ranged between 59.5 and 60.4 years; most patients were male (range, 70.6%-71.5%); mean body mass index ranged between 29.7 and 30.9; and patients receiving mechanical ventilation ranged between 50.0% and 63.5%. For the fixed-dose, shock-dependent, and no hydrocortisone groups, respectively, the median organ support-free days were 0 (IQR, -1 to 15), 0 (IQR, -1 to 13), and 0 (-1 to 11) days (composed of 30%, 26%, and 33% mortality rates and 11.5, 9.5, and 6 median organ support-free days among survivors). The median adjusted odds ratio and bayesian probability of superiority were 1.43 (95% credible interval, 0.91-2.27) and 93% for fixed-dose hydrocortisone, respectively, and were 1.22 (95% credible interval, 0.76-1.94) and 80% for shock-dependent hydrocortisone compared with no hydrocortisone. Serious adverse events were reported in 4 (3%), 5 (3%), and 1 (1%) patients in the fixed-dose, shock-dependent, and no hydrocortisone groups, respectively. Conclusions and Relevance: Among patients with severe COVID-19, treatment with a 7-day fixed-dose course of hydrocortisone or shock-dependent dosing of hydrocortisone, compared with no hydrocortisone, resulted in 93% and 80% probabilities of superiority with regard to the odds of improvement in organ support-free days within 21 days. However, the trial was stopped early and no treatment strategy met prespecified criteria for statistical superiority, precluding definitive conclusions. Trial Registration: ClinicalTrials.gov Identifier: NCT02735707

MUSiC : a model-unspecific search for new physics in proton-proton collisions at root s=13TeV

Results of the Model Unspecific Search in CMS (MUSiC), using proton-proton collision data recorded at the LHC at a centre-of-mass energy of 13 TeV, corresponding to an integrated luminosity of 35.9 fb(-1), are presented. The MUSiC analysis searches for anomalies that could be signatures of physics beyond the standard model. The analysis is based on the comparison of observed data with the standard model prediction, as determined from simulation, in several hundred final states and multiple kinematic distributions. Events containing at least one electron or muon are classified based on their final state topology, and an automated search algorithm surveys the observed data for deviations from the prediction. The sensitivity of the search is validated using multiple methods. No significant deviations from the predictions have been observed. For a wide range of final state topologies, agreement is found between the data and the standard model simulation. This analysis complements dedicated search analyses by significantly expanding the range of final states covered using a model independent approach with the largest data set to date to probe phase space regions beyond the reach of previous general searches.Peer reviewe

Measurement of prompt open-charm production cross sections in proton-proton collisions at root s=13 TeV

The production cross sections for prompt open-charm mesons in proton-proton collisions at a center-of-mass energy of 13TeV are reported. The measurement is performed using a data sample collected by the CMS experiment corresponding to an integrated luminosity of 29 nb(-1). The differential production cross sections of the D*(+/-), D-+/-, and D-0 ((D) over bar (0)) mesons are presented in ranges of transverse momentum and pseudorapidity 4 < p(T) < 100 GeV and vertical bar eta vertical bar < 2.1, respectively. The results are compared to several theoretical calculations and to previous measurements.Peer reviewe

Measurement of b jet shapes in proton-proton collisions at root s=5.02 TeV

We present the first study of charged-hadron production associated with jets originating from b quarks in proton-proton collisions at a center-of-mass energy of 5.02 TeV. The data sample used in this study was collected with the CMS detector at the CERN LHC and corresponds to an integrated luminosity of 27.4 pb(-1). To characterize the jet substructure, the differential jet shapes, defined as the normalized transverse momentum distribution of charged hadrons as a function of angular distance from the jet axis, are measured for b jets. In addition to the jet shapes, the per-jet yields of charged particles associated with b jets are also quantified, again as a function of the angular distance with respect to the jet axis. Extracted jet shape and particle yield distributions for b jets are compared with results for inclusive jets, as well as with the predictions from the pythia and herwig++ event generators.Peer reviewe

Search for supersymmetry in events with one lepton and multiple jets in proton-proton collisions at root s=13 TeV

Peer reviewe